Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

Eric T. Wong, Kenneth R. Hess, Mary Jo Gleason, Kurt A. Jaeckle, Athanassios P. Kyritsis, Michael D. Prados, Victor A. Levin, W. K. Alfred Yung

Research output: Contribution to journalArticle

720 Citations (Scopus)

Abstract

Purpose: To determine aggregate outcomes and prognostic covariates in patients with recurrent glioma enrolled onto phase II chemotherapy trials. Patients and Methods: Patients from eight consecutive phase II trials included 225 with recurrent glioblastoma multiforme (GBM) and 150 with recurrent anaplastic astrocytoma (AA). Their median age was 45 years (range, 15 to 82 years) and their median Karnofsky performance score was 80 (range, 60 to 100). Prognostic covariates were analyzed with respect to tumor response, progression-free survival (PFS), and overall survival (OS) by multivariate logistic and Cox proportional hazards regression analyses. Results: Overall, 34 (9%) had complete or partial response, whereas 80 (21%) were alive and progression-free at 6 months (APF6). The median PFS was 10 weeks and median OS was 30 weeks. Histology was a robust prognostic factor across all outcomes. GBM patients had significantly poorer outcomes than AA patients. The APF6 proportion was 15% for GBM and 31 % for AA, whereas the median PFS was 9 weeks for GBM and 13 weeks for AA. Results were also significantly poorer for patients with more than two prior surgeries or chemotherapy regimens. Conclusion: Histology is a dominant factor in determining outcome in patients with recurrent glioma enrolled onto phase II trials. Future trials should be designed with separate histology strata.

Original languageEnglish (US)
Pages (from-to)2572-2578
Number of pages7
JournalJournal of Clinical Oncology
Volume17
Issue number8
StatePublished - Aug 1999

Fingerprint

Phase II Clinical Trials
Glioma
Astrocytoma
Glioblastoma
Disease-Free Survival
Histology
Drug Therapy
Survival
Regression Analysis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Wong, E. T., Hess, K. R., Gleason, M. J., Jaeckle, K. A., Kyritsis, A. P., Prados, M. D., ... Alfred Yung, W. K. (1999). Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. Journal of Clinical Oncology, 17(8), 2572-2578.
Wong, Eric T. ; Hess, Kenneth R. ; Gleason, Mary Jo ; Jaeckle, Kurt A. ; Kyritsis, Athanassios P. ; Prados, Michael D. ; Levin, Victor A. ; Alfred Yung, W. K. / Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. In: Journal of Clinical Oncology. 1999 ; Vol. 17, No. 8. pp. 2572-2578.
@article{25c060eb6a0a439d8c36f3758836af18,
title = "Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials",
abstract = "Purpose: To determine aggregate outcomes and prognostic covariates in patients with recurrent glioma enrolled onto phase II chemotherapy trials. Patients and Methods: Patients from eight consecutive phase II trials included 225 with recurrent glioblastoma multiforme (GBM) and 150 with recurrent anaplastic astrocytoma (AA). Their median age was 45 years (range, 15 to 82 years) and their median Karnofsky performance score was 80 (range, 60 to 100). Prognostic covariates were analyzed with respect to tumor response, progression-free survival (PFS), and overall survival (OS) by multivariate logistic and Cox proportional hazards regression analyses. Results: Overall, 34 (9{\%}) had complete or partial response, whereas 80 (21{\%}) were alive and progression-free at 6 months (APF6). The median PFS was 10 weeks and median OS was 30 weeks. Histology was a robust prognostic factor across all outcomes. GBM patients had significantly poorer outcomes than AA patients. The APF6 proportion was 15{\%} for GBM and 31 {\%} for AA, whereas the median PFS was 9 weeks for GBM and 13 weeks for AA. Results were also significantly poorer for patients with more than two prior surgeries or chemotherapy regimens. Conclusion: Histology is a dominant factor in determining outcome in patients with recurrent glioma enrolled onto phase II trials. Future trials should be designed with separate histology strata.",
author = "Wong, {Eric T.} and Hess, {Kenneth R.} and Gleason, {Mary Jo} and Jaeckle, {Kurt A.} and Kyritsis, {Athanassios P.} and Prados, {Michael D.} and Levin, {Victor A.} and {Alfred Yung}, {W. K.}",
year = "1999",
month = "8",
language = "English (US)",
volume = "17",
pages = "2572--2578",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "8",

}

Wong, ET, Hess, KR, Gleason, MJ, Jaeckle, KA, Kyritsis, AP, Prados, MD, Levin, VA & Alfred Yung, WK 1999, 'Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials', Journal of Clinical Oncology, vol. 17, no. 8, pp. 2572-2578.

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. / Wong, Eric T.; Hess, Kenneth R.; Gleason, Mary Jo; Jaeckle, Kurt A.; Kyritsis, Athanassios P.; Prados, Michael D.; Levin, Victor A.; Alfred Yung, W. K.

In: Journal of Clinical Oncology, Vol. 17, No. 8, 08.1999, p. 2572-2578.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

AU - Wong, Eric T.

AU - Hess, Kenneth R.

AU - Gleason, Mary Jo

AU - Jaeckle, Kurt A.

AU - Kyritsis, Athanassios P.

AU - Prados, Michael D.

AU - Levin, Victor A.

AU - Alfred Yung, W. K.

PY - 1999/8

Y1 - 1999/8

N2 - Purpose: To determine aggregate outcomes and prognostic covariates in patients with recurrent glioma enrolled onto phase II chemotherapy trials. Patients and Methods: Patients from eight consecutive phase II trials included 225 with recurrent glioblastoma multiforme (GBM) and 150 with recurrent anaplastic astrocytoma (AA). Their median age was 45 years (range, 15 to 82 years) and their median Karnofsky performance score was 80 (range, 60 to 100). Prognostic covariates were analyzed with respect to tumor response, progression-free survival (PFS), and overall survival (OS) by multivariate logistic and Cox proportional hazards regression analyses. Results: Overall, 34 (9%) had complete or partial response, whereas 80 (21%) were alive and progression-free at 6 months (APF6). The median PFS was 10 weeks and median OS was 30 weeks. Histology was a robust prognostic factor across all outcomes. GBM patients had significantly poorer outcomes than AA patients. The APF6 proportion was 15% for GBM and 31 % for AA, whereas the median PFS was 9 weeks for GBM and 13 weeks for AA. Results were also significantly poorer for patients with more than two prior surgeries or chemotherapy regimens. Conclusion: Histology is a dominant factor in determining outcome in patients with recurrent glioma enrolled onto phase II trials. Future trials should be designed with separate histology strata.

AB - Purpose: To determine aggregate outcomes and prognostic covariates in patients with recurrent glioma enrolled onto phase II chemotherapy trials. Patients and Methods: Patients from eight consecutive phase II trials included 225 with recurrent glioblastoma multiforme (GBM) and 150 with recurrent anaplastic astrocytoma (AA). Their median age was 45 years (range, 15 to 82 years) and their median Karnofsky performance score was 80 (range, 60 to 100). Prognostic covariates were analyzed with respect to tumor response, progression-free survival (PFS), and overall survival (OS) by multivariate logistic and Cox proportional hazards regression analyses. Results: Overall, 34 (9%) had complete or partial response, whereas 80 (21%) were alive and progression-free at 6 months (APF6). The median PFS was 10 weeks and median OS was 30 weeks. Histology was a robust prognostic factor across all outcomes. GBM patients had significantly poorer outcomes than AA patients. The APF6 proportion was 15% for GBM and 31 % for AA, whereas the median PFS was 9 weeks for GBM and 13 weeks for AA. Results were also significantly poorer for patients with more than two prior surgeries or chemotherapy regimens. Conclusion: Histology is a dominant factor in determining outcome in patients with recurrent glioma enrolled onto phase II trials. Future trials should be designed with separate histology strata.

UR - http://www.scopus.com/inward/record.url?scp=0032767387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032767387&partnerID=8YFLogxK

M3 - Article

C2 - 10561324

AN - SCOPUS:0032767387

VL - 17

SP - 2572

EP - 2578

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 8

ER -

Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. Journal of Clinical Oncology. 1999 Aug;17(8):2572-2578.